RecruitingNot ApplicableNCT07367581

Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer

Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial


Sponsor

National Cancer Institute, Egypt

Enrollment

70 participants

Start Date

Jan 24, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Age \> 18 years and ≤ 65 years old.
  • American Society of Anesthesiologists (ASA) physical status II-III.
  • Body mass index 18-35 kg/m2.
  • Patients scheduled for thoracotomies for lung cancer.

Exclusion Criteria8

  • Patient refusal.
  • History of sensitivity to local anesthetics.
  • History of psychological disorders.
  • Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy.
  • Severe respiratory, cardiac, hepatic, or renal disease.
  • Morbid obesity.
  • Uncooperative patients.
  • Patients on chronic pain therapy.

Interventions

OTHERCostotransverse foramen block

Patients will receive an ipsilateral ultrasound-guided costotransverse foramen block with injection of 20 ml bupivacaine 0.25%.

OTHERThoracic paravertebral plane block

Patients will receive an ipsilateral ultrasound-guided thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25%.


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07367581


Related Trials